

FlowCellect[™] Mouse Treg Differentiation Tool Kit 12 Tests

Cat. No. FCIM025166

FOR RESEARCH USE ONLY Not for use in diagnostic procedures.

USA & Canada Phone: +1 (800) 437-7500 Fax: +1 (951) 676-9209 www.millipore.com

Application

CD4⁺ T cells play a central role in the function of the immune system: They help B cells produce antibodies, enhance and maintain responses of CD8⁺ T cells, regulate macrophage function, orchestrate immune responses against a wide variety of pathogenic microorganisms, and regulate immune responses (1).

Effector T cells are derived from naïve CD4⁺ progenitor T cells, after maturational complex interactions with antigen-presenting cells in a permissive milieu, including antigenic type and load, and cytokine signaling. Committed CD4⁺ T cells can differentiate into four major lineages: Th1, Th2, Th17 and regulatory T cells with distinct cytokine products and biological functions (2-4).

Tregs play a vital role in regulating the responses of the immune system. They suppress the activation of the immune system following infections, which helps maintain immune homeostasis. It has also been shown that some cancer patients have increased numbers of Tregs which may allow some malignant cells to escape the activation of the immune system due to the suppressive nature of the Tregs (5-8).

In vitro generated mouse induced Treg cells have been utilized for intracellular cytokine analysis using flow cytometry, secreted cytokine analysis by ELISA or Luminex and *in vivo* transplantations for adoptive immunotherapy (9, 10).

EMD-Millipore's FlowCellect[™] Mouse Treg Differentiation Tool Kit is a complete primary culture system designed for the optimal differentiation of naive CD4⁺ cells into Treg polarized cells.

Assay Principle

The FlowCellect Mouse[™] Treg Differentiation Tool Kit includes a CD3 Coated Activation Plate, complete Differentiation Media and Activators. Detailed assay instructions are included to assist in two culture steps: Activation and Expansion to complete Treg cell generation in 7 days.

Day 1=Activation: Culture CD4+ cells with growth factors on an anti-CD3 coated 96-well plate for 3 days.

Day 4=Expansion: Expand activated/developing Treg cells in a larger tissue culture plate.

Day 7=Harvest: Differentiated Treg cells are harvested for Foxp3, CD25 and CD4 expression analysis.




Figure 1. Overview of the differentiation process.

CD4+ Splenocytes are differentiated to the induced Treg lineage with single addition of an activator mixture on day 1 and day 4, then harvested on day 7 for Foxp3, CD25 and CD4 analysis.




Fig. 2 Cytokine Balance in Effector T Cell Differentiation

Each type of effector T cell counter balances each other to achieve immune homeostasis. For example, IL-6 induces Th17 differentiation, however it inhibits the Trea lineage. In vitro Treg differentiation assay, Treg activator TGFbeta is added in the culture along with neutralizing antibody anti-IL-6 to enhance and maintain the lineage commitment. Thus, cytokines play crucial roles as both agonists and antagonists for the lineage.

Kit Components

FCIM025166-1 (2-8 °C)

- <u>Mouse CD3 Coated Activation Plate</u>: (Part No. CS206556) One 96-well plate with strips
- <u>Treg Activator #1:</u> (Part No. CS206530) One vial containing 12 µL of neutralizing antibodies
- <u>Differentiation Media</u>: (Part No. CS206524) One vial containing 200 mL of complete Treg differentiation culture media

FCIM025166-2 (-20 °C)

<u>Treg Activator #2</u>: (Part No.CS206531) One vial containing lyophilized growth factors

Materials Not Supplied

- 1. Mouse CD4⁺ enriched splenocytes
- 2. 24-well tissue culture plates
- 3. Pipettors with corresponding tips capable of accurately measuring 0.1 1000 μ L
- 4. Tabletop centrifuge capable of achieving 600 x g
- 5. Sterile Deionized water
- FlowCellect[™] Mouse Viable Treg Characterization Kit (Viability Dye, Conjugated antibodies for detection of CD4, CD25, and Foxp3).
 Cat. No. FCIM025168
- 7. Scepter Cell counter. Cat. No. PHCC20040

Precautions

- 1 The instructions provided have been designed to optimize the kit's performance. Deviation from the kit's instructions may result in suboptimal performance and may produce inaccurate data.
- 2 Wear proper laboratory attire (lab coat, gloves, safety glasses) when handling or using this product.
- 3 Some assay components included in the kit may be harmful. Please refer to the MSDS sheet for specific information on hazardous materials (MSDS forms can be obtained by contacting Millipore technical services).
- 4 During storage and shipment, small volumes of product will occasionally become entrapped in the seal of the product vial. For maximum recovery of product, centrifuge vial briefly prior to removing cap.
- 5 Avoid microbial contamination of all solutions, which may cause erroneous results.
- 6 Do not use reagents beyond their expiration date.

Storage/Handling

- Anti-CD3 Coated 96-well Activation Plate, Differentiation Media and Treg Activator #1 must be stored at 2 – 8 °C. Unopened vial of lyophilized Treg Activator #2 must be stored at -20 °C.
- After combined Treg Activator #1 and #2, the mixture must be stored at 2 8 °C.

All kit components are stable up to six (4) months from date of receipt if stored and handled correctly. **Please avoid repeated changes in temperature as this will affect the integrity of the product.**

Preparation of Reagents

Note: Perform all steps under a certified tissue culture hood using sterile materials and aseptic technique.

- Reconstitution of Treg Activator #2; After a brief spin, reconstitute in 140 μL of sterile water and mix by gentle pipetting then spin down again. Make sure that all lyophilized powder is dissolved in water. Avoid repeated freeze and thaw cycles.
- Mixture of Treg Activator #1 and #2; Transfer 30 μL of reconstituted Treg Activator #2 into Treg Activator #1 vial. Once combined, the mixture must be stored at 2 – 8 °C. See Figure 3.

Note: After making Treg Activator #1 and #2 mixture, keep unused portion of Activator #2 at 2 - 8 °C for the Day 4 expansion step.





Figure 3. Reconstitution and Mixing of Activation Reagent.

3. CD3 Coated Activation Plate: Pre-warm strips needed at RT.

Note: Anti-CD3 antibody is coated only on 12 wells of Row A (from well #A1 to A12). Unused strips should be kept in sterile condition in the foil pouch with desiccant provided and stored at 2-8 °C. The strips only fit in one direction on the plate so Row A will always contain the coated wells.



4. Differentiation Media: Pre-warm media at RT.

5. Preparation of Cells:

Isolate CD4⁺ T cells from mouse splenocytes with your preferred sorting method. We recommend starting with CD4⁺ T cell enriched splenocytes with more than 90% CD4⁺ purity and 90% viability.

Assay Instructions

Note: This assay protocol has been optimized for naïve CD4+ enriched splenocytes derived from both naïve BALB/c and C57BL strains, 7-12 week-old mice. Other strains have not been tested, but, are expected to perform similarly.

Protocol for Treg Differentiation

Note: Perform all steps including reagent preparations under a certified tissue culture hood using sterile materials and aseptic technique. Keep all activator vials on ice. Pre-warm the plate and media at RT.

Day 1: Start Activation of Naïve CD4+ T Cells

Materials for Day 1

- CD3 Coated Activation Plate
- Mixture of Treg Activator #1 and #2 (See "Preparation of Reagents" section for details)
- Differentiation Media
- □ CD4⁺ enriched splenocytes not included
- 1. Prepare CD4+ enriched splenocytes.
- 2. Wash cells with Differentiation Media once and resuspend in Differentiation Media at a concentration of 8X10⁵ cells / mL.
- 3. Plate $2X10^5$ cells (250 µL) into a CD3 coated well on Row A.
- 4. Apply 3 µL of mixture of Treg Activator #1and #2 to each well. Mix well.
- 5. Place the 96-well plate at 37 °C in a CO₂ humidified incubator for 3 days.

Day 4 : Expansion of Activated Treg Cells

Materials for Day 4


- Mixture of Treg Activator #2
- Differentiation Media
- 24-well plate not included

Expand activated cells at 1:10 in Differentiation Media. We recommend using single well of a 24-well plate.

Note: Cells should start blasting and forming small cell aggregates which can be seen under a microscope at this point in the culture.

24-well plate:

- 6. Suspend Treg activated cells in the CD3 Coated Activation 96-well Plate vigorously by pipeting up side down and scraping out from bottom of the well with pippet tip.
- 7. Transfer 200 μ L of the activated cell suspension from a 96-well plate to a single well of a 24-well plate.



- 8. Apply 1.8 mL of Differentiation Media to each well for a total media volume of 2.0 mL.
- 9. Apply 8 µL of Treg Activator #2 to each well.
- 10. Incubate at 37 °C in a CO₂ humidified incubator for 3 days.

Day 7: Harvest

On day 7, differentiated Treg cells are harvested for Foxp3, CD25 and CD4 analysis. Total cell numbers should be approximately 1-5 X10⁶ per well by day 7.

Sample Data

Intracellular Cytokine Analysis by Guava Flow Cytometry using FlowCellect™ Mouse Viable Treg Characterization Kit.




Figure 4: Representative flow cytometric data of mouse naïve splenocytes (top panels A and B) and following a 7 day directed differentiation to the Treg lineage with optimized growth factor and antibody cocktails (bottom panels C and D). The samples were stained with Fixable Viability Dye to gate out dead cells and only live cells were analyzed for anti-Foxp3/CD4 (left column A and C) or anti-Foxp3/CD25 (right column B and D).

Troubleshooting

To obtain reliable and producible results the operator should carefully read this manual and fully understand all aspects of each assay step before beginning the culture.

Assay Step	Potential Problem	Experimental Suggestions
Reagent Preparation		 If storing at -20 °C or for lyophilized agents, place tubes at room temperature and briefly spin, prior to use.
		 After reconstitution of Activator #2 with sterile water, set the vial at room temperature for 5 minutes to allow powder to dissolve completely and spin briefly.
Culture	Poor cell proliferation	• Cells should start blasting and proliferating by the end of 2 nd day of the culture. Check cells under a microscope and see if you see any morphological changes such as increase in cell size or irregular cell shape as shown in pictures on page XX in this manual.
		 Check an orientation of cell culture strip on 96-well plate and make sure CD3-coated wells are used. The strips only fit one way so use only 12 wells of Row A. Wells of from row B to H are non-coated; using these wells gives no TCR activation which is required for the primary CD4+ cell proliferation.
		 Check Activator #1 for Day 1 culture and make sure Activator #2 was added correctly. If you did not add this mixture on day1, add 0.5 μL of Activator #2 ONLY on day 2 (not the mixture of #1 and #2) and incubate another 3 days.
Culture	Many cell death	 A concentration of cells was too low or too high. Count cells on day 1 before plating cells as well as on day 6 before re-stimulation. Make sure you use right cell concentration which we suggested in this manual.
		 Check an orientation of cell culture strip on 96-well plate and make sure CD3-coated wells are used. The strips only fit one way so use only 12 wells of Row A. Wells of from row B to H are non-coated; using these wells gives no TCR activation which is required for the primary CD4+ cell proliferation.
Culture	contamination	 Check all material used was sterile including cell preparation step and water added for reconstitution of Activator(s). All materials in this kit are provided as sterile.

*For further support, please contact Millipore's Technical services at +1(800) 437-7500

Technical Hints

- For activation and differentiation to be most effective, make sure that enriched CD4+ cells have good viability and purity prior to culture.
- Perform all steps including reagent preparations under a certified culture food using sterile materials and aseptic technique.
- Expansion and re-stimulation steps can be scaled up and down for your needs. Make sure that you have enough reagents before alter the protocols.
- Do not mix or interchange reagents from various kit lots.
- Use a Scepter for performing cell counts to reduce the amount of sample loss during determination of cell concentrations.

References

- 1. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. *Annu Rev Immunol.* 2010;28:445-89.
- 2. Zhou L, Chong MM, Littman DR. Plasticity of CD4+ T cell lineage differentiation. *Immunity.* 2009;30:646-55.
- 3. Wan YY, Flavell RA. How diverse--CD4 effector T cells and their functions. *J Mol Cell Biol.* 2009;1:20-36.
- 4. Fietta P, Delsante G. The effector T helper cell triade. Riv Biol. 2009;102:61-74.
- 5. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. *Blood.* 2008; 112: 1557-69.
- 6. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. *Science*. 2003;299:1057-61.
- Earle KE, Tang Q, Zhou X, Liu W, Zhu S, Bonyhadi ML, Bluestone JA. In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. *Clin Immunol.* 2005;115:3-9
- 8. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. *Nat Immunol.* 2005;6:345-52.
- 9. Zou W. Regulatory T cells, tumour immunity and immunotherapy. *Nat Rev Immunol.* 2006;6:295-307.
- 10. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. *Nat Rev Cancer*. 2007;7:880-7.

Related Products

FCIM025123	FlowCellect™ Mouse Th1 Intracellular Cytokine Kit
FCIM025124	FlowCellect™ Mouse Th2 Intracellular Cytokine Kit
FCIM025125	FlowCellect™ Mouse Th17 Intracellular Cytokine Kit
FCIM025137	FlowCellect™ Mouse Th1/Th2 Intracellular Cytokine Kit
FCIM025138	FlowCellect™ Mouse Th1/Th17 Intracellular Cytokine Kit
FCIM025154	FlowCellect™ Mouse Breg Characterization Kit
FCIM025168	FlowCellect™ Mouse Viable Treg Characterization Kit
FCIM025159	FlowCellect™ Human Memory B Cell Function Kit
FCIM025118	FlowCellect™ Human FOXP3 Treg Characterization Kit
FCIM025161	FlowCellect [™] Mouse Th1 Differentiation Tool Kit
FCIM025162	FlowCellect™ Mouse Th2 Differentiation Tool Kit
FCIM025163	FlowCellect [™] Mouse Th17 Differentiation Tool Kit

WARRANTY

Millipore Corporation ("Millipore") warrants its products will meet their applicable published specifications when used in accordance with their applicable instructions for a period of one year from shipment of the products. MILLIPORE MAKES NO OTHER WARRANTY, EXPRESSED OR IMPLIED. THERE IS NO WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. The warranty provided herein and the data, specifications and descriptions of Millipore products appearing in Millipore's published catalogues and product literature may not be altered except by express written agreement signed by an officer of Millipore. Representations, oral or written, which are inconsistent with this warranty or such publications are not authorized and if given, should not be relied upon.

In the event of a breach of the foregoing warranty, Millipore's sole obligation shall be to repair or replace, at its option, the applicable product or part thereof, provided the customer notifies Millipore promptly of any such breach. If after exercising reasonable efforts, Millipore is unable to repair or replace the product or part, then Millipore shall refund to the Company all monies paid for such applicable Product. MILLIPORE SHALL NOT BE LIABLE FOR CONSEQUENTIAL, INCIDENTAL, SPECIAL OR ANY OTHER DAMAGES RESULTING FROM ECONOMIC LOSS OR PROPERTY DAMAGE SUSTAINED BY ANY COMPANY CUSTOMER FROM THE USE OF ITS PRODUCTS.

(c) 2011: Millipore Corporation. All rights reserved. No part of these works may be reproduced in any form without permission in writing.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

FCIM025166

FCIM025166MAN June 2011 Rev.B